↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Perry BD, U'Prichard DC (December 1981). „[3H]rauwolscine (alpha-yohimbine): a specific antagonist radioligand for brain alpha 2-adrenergic receptors”. European Journal of Pharmacology76 (4): 461–4. DOI:10.1016/0014-2999(81)90123-0. PMID6276200.
↑Arthur JM, Casañas SJ, Raymond JR (June 1993). „Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors”. Biochemical Pharmacology45 (11): 2337–41. DOI:10.1016/0006-2952(93)90208-E. PMID8517875.
↑Kaumann AJ (June 1983). „Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors”. Naunyn-Schmiedeberg's Archives of Pharmacology323 (2): 149–54. DOI:10.1007/BF00634263. PMID6136920.
↑Wainscott DB, Sasso DA, Kursar JD, Baez M, Lucaites VL, Nelson DL (January 1998). „[3HRauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor”]. Naunyn-Schmiedeberg's Archives of Pharmacology357 (1): 17–24. DOI:10.1007/PL00005133. PMID9459568.